Drug Profile
Chimeric antigen receptor T-cell therapy - Hunan Zhaotai Yongren Biotech/Hunan Yongren Medical Innovation
Alternative Names: Z-CTLs; Zeushield Cytotoxic T LymphocytesLatest Information Update: 13 Nov 2021
Price :
$50
*
At a glance
- Originator Hunan Yongren Medical Innovation; Hunan Zhaotai Yongren Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral, Infusion)
- 12 Feb 2017 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT03060343)